ACADIA PHARMACEUTICALS INC — Director's Dealing 2019

Dec 11, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2019-12-09

Reporting Person: Ridloff Elena (EVP and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-09	Common Stock	M	36000	$15.81	Acquired	36000	Direct
2019-12-09	Common Stock	S	11020	$50.595	Disposed	24980	Direct
2019-12-09	Common Stock	S	5502	$49.808	Disposed	19478	Direct
2019-12-09	Common Stock	S	19478	$49.094	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-09	Stock Option (Right to Buy)	$15.81	M	36000	Disposed	2028-04-29	Common Stock (36000)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2019.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.17 to $51.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $50.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.75 to $49.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F5: 25% of the 100,000 shares originally subject to the stock option vested and became exercisable on April 30, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.